April 04, 2023
A Provention Bio Inc. investor has filed a lawsuit seeking to delay the biopharmaceutical company's pending $2.9 billion equity merger with Sanofi SA until it explains the deal's financial justification and alleged conflicts of interest — information that was purportedly concealed in filings and regulatory filings encouraging shareholders to accept a tender offer.